NovaBridge Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	228.06	68.26	291.51	465.99	554.68	728.91
Short-Term Investments	0.21	105.14	20.22	34.8	118.56	4.83
Cash & Short-Term Investments	228.27	173.4	311.73	500.78	673.24	733.74
Cash Growth	-	-44.38%	-37.75%	-25.61%	-8.25%	336.86%
Accounts Receivable	-	-	-	-	45.16	54.82
Other Receivables	0.93	1.17	1.83	4.81	16	16.54
Receivables	0.93	1.17	1.83	4.81	61.16	71.36
Inventory	-	-	-	-	4.29	-
Prepaid Expenses	1.47	1.13	0.12	1.38	1.41	0.39
Restricted Cash	-	-	-	14.03	-	-
Other Current Assets	2.1	1	16.23	4.78	12.62	13.01
Total Current Assets	232.78	176.69	329.91	525.79	752.72	818.5
Property, Plant & Equipment	3.17	3.8	5.55	17.97	24.95	6.17
Long-Term Investments	40.32	30.82	-	4.47	55.43	101.83
Goodwill	-	-	-	23.57	25.59	24.9
Other Intangible Assets	-	-	-	17.24	18.84	18.45
Other Long-Term Assets	1.15	1.37	33.46	1.58	4.19	0.31
Total Assets	277.41	212.68	368.92	590.63	881.72	970.16
Accrued Expenses	8.03	7.53	6.58	100.48	92.27	65.46
Short-Term Debt	-	-	-	2.75	-	-
Current Portion of Leases	0.87	0.82	0.63	3.47	4.83	1.23
Current Unearned Revenue	-	-	-	1.26	-	1.15
Other Current Liabilities	7.19	0.11	50.94	1.96	1.13	20.41
Total Current Liabilities	16.09	8.45	58.14	109.92	98.23	88.25
Long-Term Leases	2.4	3.07	3.26	4.65	12.87	0.85
Long-Term Unearned Revenue	-	-	-	38.84	35.26	-
Other Long-Term Liabilities	-	-	64.93	15.32	17.61	19.14
Total Liabilities	18.5	11.52	126.34	168.73	163.97	108.24
Common Stock	0.03	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	1,523	1,460	1,475	1,389	1,433	1,180
Retained Earnings	-1,302	-1,286	-1,264	-994.92	-685.52	-309.91
Treasury Stock	-5.24	-6.23	-8.01	-3.08	-	-
Comprehensive Income & Other	42.89	33.38	39.77	31	-29.36	-7.78
Total Common Equity	258.92	201.16	242.58	421.9	717.75	861.92
Shareholders' Equity	258.92	201.16	242.58	421.9	717.75	861.92
Total Liabilities & Equity	277.41	212.68	368.92	590.63	881.72	970.16
Total Debt	3.28	3.88	3.89	10.87	17.7	2.08
Net Cash (Debt)	225	169.52	307.84	489.91	655.53	731.66
Net Cash Growth	-	-44.93%	-37.16%	-25.26%	-10.41%	391.28%
Net Cash Per Share	2.58	2.09	3.70	5.94	8.63	10.70
Filing Date Shares Outstanding	115.29	81.5	80.7	82.99	82.55	72.41
Total Common Shares Outstanding	115.29	81.5	80.7	82.99	79.92	71.69
Working Capital	216.68	168.24	271.77	415.87	654.49	730.25
Book Value Per Share	2.25	2.47	3.01	5.08	8.98	12.02
Tangible Book Value	258.92	201.16	242.58	381.09	673.32	818.57
Tangible Book Value Per Share	2.25	2.47	3.01	4.59	8.42	11.42
Machinery	-	0.43	1.77	9.33	6.1	4.95
Construction In Progress	-	-	-	0.9	3.32	-
Leasehold Improvements	-	-	0.87	5.42	2.98	2.12

Source: S&P Global Market Intelligence. Standard template. Financial Sources.